Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Creation and implementation of a European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC registry)

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. The need for widely available genomic testing in rare eye diseases: an ERN-EYE position statement

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Clinical disease progression and biomarkers in Niemann-Pick disease type C: a prospective cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Data from the European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The SPARKLE registry: protocol for an international prospective cohort study in patients with alpha-mannosidosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Episodic hyperCKaemia may be a feature of α-methylacyl-coenzyme A racemase deficiency

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Data from the European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Mutation Load of Single, Large-Scale Deletions of mtDNA in Mitotic and Postmitotic Tissues

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • EUROMAC Consortium
Vis graf over relationer

BACKGROUND: International patient registries are of particular importance for rare disorders, as they may contribute to overcome the lack of knowledge derived from low number of patients and limited awareness of these diseases, and help to learn more about their geographical or population-based specificities, which is relevant for research purposes and for promoting better standards of care and diagnosis. Our objective was to create and implement a European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC) and to disseminate the knowledge of these disorders.

RESULTS: Teams from nine different countries (United Kingdom, Spain, Italy, France, Germany, Denmark, Greece, Turkey and USA) created a consortium that developed the first European registry dedicated to rare muscle glycogenoses. A work plan was implemented to design the database and platform that constitute the registry, by choosing clinical, genetics and molecular variables of interest, based on experience gained from previous national registries for similar metabolic disorders. Among dissemination activities, several teaching events were organized in different countries, especially those where the consortium considered the awareness of these diseases needs to be promoted among health professionals and patients.

CONCLUSION: EUROMAC represents a step forward in the knowledge of those disorders to which it is dedicated, and will have relevant clinical outcomes at the diagnostic, epidemiological, clinical and research level.

OriginalsprogEngelsk
Artikelnummer187
TidsskriftOrphanet Journal of Rare Diseases
Vol/bind15
Udgave nummer1
Sider (fra-til)187
ISSN1750-1172
DOI
StatusUdgivet - 15 okt. 2020

ID: 61072032